Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
STAT24d
Editas tacks again, steering from lead sickle cell treatment to new one
the latest shift for a tarantella company that has repeatedly switched direction and leadership since first emerging as one of the first CRISPR biotechs a decade ago. Editas will now focus ...
Swissinfo7d
Swiss researchers find unwanted CRISPR side effects
CRISPR gene editing can have unforeseen consequences on the structure of chromosomes, says the University of Zurich.
The New England Journal of Medicine22d
CRISPR-Based Therapy for Hereditary Angioedema
NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR ... the estimated mean monthly attack rate was 0.70 ...